Valuation: Myriad Genetics, Inc.

Market Cap 524M 477M 440M 400M 750M 48.5B 788M 5.35B 2.13B 26.49B 1.97B 1.92B 83.13B P/E 2026 *
-3.17x
P/E 2027 * -4.14x
Enterprise Value 478M 435M 401M 365M 684M 44.23B 719M 4.88B 1.94B 24.16B 1.79B 1.75B 75.82B EV / Sales 2026 *
0.61x
EV / Sales 2027 * 0.36x
Free-Float
96.01%
Yield 2026 *
-
Yield 2027 * -
1 day-1.44%
1 week-3.53%
Current month-14.02%
1 month-1.97%
3 months+70.62%
6 months+39.64%
Current year-11.22%
1 week 5.3
Extreme 5.305
5.74
1 month 5.3
Extreme 5.305
6.77
Current year 2.74
Extreme 2.74
7.15
1 year 2.74
Extreme 2.74
8.08
3 years 2.74
Extreme 2.74
29.3
5 years 2.74
Extreme 2.74
29.3
10 years 2.74
Extreme 2.74
50.44
Manager TitleAgeSince
Chief Executive Officer 54 2025-04-29
Director of Finance/CFO 43 2025-08-15
Chief Tech/Sci/R&D Officer - 2026-05-31
Director TitleAgeSince
Chairman 67 2020-03-22
Director/Board Member 71 2010-06-09
Director/Board Member 66 2019-09-24
Date Insider Type Main position Quantity % Market Cap. Importance
11/1/26 Free

General Counsel

39,370 0.0412%
9/21/26 Tax

Chief Financial Officer

-2,555 0.0027%
9/16/26 Free

Executive/Senior Manager

257,731 0.2695%
Change 5-day change 1-year change 3-year change Capi.($)
-1.44%-3.53%-26.02%-68.76% 524M
-0.84%-5.09%-19.60%+1.07% 178B
-0.67%-2.84%-1.25%+27.12% 122B
-0.98%+0.12%-15.82%+5.56% 118B
-1.24%-4.25%-42.94%-1.34% 88.1B
-0.63%-5.55%-7.27%+70.54% 64.71B
+0.05%-2.41%+10.41%-9.90% 57.96B
-1.95%-3.98%-6.85%+41.55% 53.28B
-2.91%-4.35%-0.97%+38.45% 47.8B
-1.64%+1.50%+1.30%-2.04% 35.65B
Average -1.22%-2.72%-10.90%+10.22% 77B
Weighted average by Cap. -1.04%-2.97%-12.45%+15.62%

Financials

2026 *2027 *
Net sales 786M 716M 660M 600M 1.13B 72.77B 1.18B 8.03B 3.19B 39.75B 2.95B 2.89B 125B 689M 627M 578M 526M 986M 63.78B 1.04B 7.03B 2.8B 34.83B 2.58B 2.53B 109B
Net income -158M -144M -133M -121M -227M -14.66B -238M -1.62B -643M -8.01B -594M -581M -25.13B -93.52M -85.18M -78.49M -71.39M -134M -8.66B -141M -955M -380M -4.73B -351M -343M -14.84B
Net Debt -46.1M -41.99M -38.69M -35.19M -66.02M -4.27B -69.39M -471M -187M -2.33B -173M -169M -7.32B -274M -250M -230M -209M -393M -25.39B -413M -2.8B -1.11B -13.87B -1.03B -1.01B -43.51B
Projected Income Statement - Annual - Myriad Genetics, Inc.
Logo Myriad Genetics, Inc.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Employees
2,700
Date Price Change Volume
26-11-20 $5.460 -1.44% 1,248,897
26-11-19 $5.540 +0.18% 1,168,029
26-11-18 $5.530 -0.18% 1,257,046
26-11-17 $5.540 -0.54% 1,119,063
26-11-16 $5.570 -1.59% 1,117,320
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - Myriad Genetics, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
5.460USD
Average target price
5.900USD
Spread / Average Target
+8.06%
  1. Stock Market
  2. Stocks
  3. MYGN Stock